GlassScriptPhysician profile
Nader Kashani
NPI 1285793893
$1,586.58
in general payments reported to CMS, 2019-2025
21 companies · $371 in 2025
The $371 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.93 · 2020: $302 · 2021: $161 · 2022: $292 · 2023: $30.02 · 2024: $411 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $687 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $687.36 |
| Education | $125.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $178.07 | 2020-2025 | Tagrisso, Imfinzi |
| Astellas Pharma US INC | $151.14 | 2020-2025 | Xtandi, Vyloy |
| Ethicon INC. | $147.01 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $139.25 | 2021 | |
| Karyopharm Therapeutics INC. | $121.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $118.11 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $114.84 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $100.62 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $77.90 | 2020-2025 | |
| Seagen INC. | $59.26 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $55.93 | 2024 | Opdualag |
| Coherus Oncology, INC. | $52.11 | 2024-2025 | Loqtorzi |
| Daiichi Sankyo INC. | $45.85 | 2021-2025 | Vanflyta |
| Kite Pharma, INC. | $33.95 | 2019-2025 | Yescarta |
| Agios Pharmaceuticals, INC. | $33.06 | 2024 | Pyrukynd |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $32.04 | 2024 | Ninlaro |
| Menarini Silicon Biosystems, INC. | $30.02 | 2023 | Cellsearch |
| Pfizer INC. | $28.10 | 2025 | |
| Incyte Corporation | $23.95 | 2024 | Jakafi |
| Stemline Therapeutics INC. | $23.77 | 2024 | Orserdu |
| Kyowa Kirin, INC. | $19.94 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Kashani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.